POULIMENEAS, Dimitrios, Markela KONIORDOU, Dimitra KOUSI, Christina MERAKOU, Ioannis KOPSIDAS, Grammatiki Christina TSOPELA, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, George SHIAMAKKIDES, Marinos CONSTANTINOU, Alexandra ALEXANDROU, Evgenia NOULA, Andria NEARCHOU, Jon SALMANTON-GARCÍA, Fiona A STEWART, Sarah HERINGER, Kerstin ALBUS, Elena ÁLVAREZ-BARCO, Alan MACKEN, Romina Di MARZO, Catarina LUIS, Paula VALLE-SIMÓN, Helena H ASKLING, Margot HELLEMANS, Orly SPIVAK, Ruth Joanna DAVIS, Anna Maria AZZINI, Imre BARTA, Lenka SOUČKOVÁ, Ligita JANCORIENE, Murat AKOVA, Patrick W G MALLON, Ole F OLESEN, Jesus FRIAS-INIESTA, Pierre van DAMME, Krisztina TÓTH, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA, Pontus NAUCLÉR, Laura MARQUES, Jordi OCHANDO, Evelina TACCONELLI, Markus ZEITLINGER, Oliver A CORNELY, Zoi Dorothea PANA and Theoklis E ZAOUTIS. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium. Vaccines. Basel: MDPI, 2023, vol. 11, No 12, p. 1784-1795. ISSN 2076-393X. Available from: https://dx.doi.org/10.3390/vaccines11121784.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium
Authors POULIMENEAS, Dimitrios, Markela KONIORDOU, Dimitra KOUSI, Christina MERAKOU, Ioannis KOPSIDAS, Grammatiki Christina TSOPELA, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, George SHIAMAKKIDES, Marinos CONSTANTINOU, Alexandra ALEXANDROU, Evgenia NOULA, Andria NEARCHOU, Jon SALMANTON-GARCÍA, Fiona A STEWART, Sarah HERINGER, Kerstin ALBUS, Elena ÁLVAREZ-BARCO, Alan MACKEN, Romina Di MARZO, Catarina LUIS, Paula VALLE-SIMÓN, Helena H ASKLING, Margot HELLEMANS, Orly SPIVAK, Ruth Joanna DAVIS, Anna Maria AZZINI, Imre BARTA, Lenka SOUČKOVÁ (203 Czech Republic, belonging to the institution), Ligita JANCORIENE, Murat AKOVA, Patrick W G MALLON, Ole F OLESEN, Jesus FRIAS-INIESTA, Pierre van DAMME, Krisztina TÓTH, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA (203 Czech Republic, belonging to the institution), Pontus NAUCLÉR, Laura MARQUES, Jordi OCHANDO, Evelina TACCONELLI, Markus ZEITLINGER, Oliver A CORNELY, Zoi Dorothea PANA and Theoklis E ZAOUTIS.
Edition Vaccines, Basel, MDPI, 2023, 2076-393X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30303 Infectious Diseases
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.800 in 2022
RIV identification code RIV/00216224:14110/23:00132500
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/vaccines11121784
UT WoS 001131427300001
Keywords in English barriers; COVID-19; Europe; pandemic preparedness; SARS-CoV-2; vaccinations; vaccine education; vaccine trials
Tags 14110214, 14110516, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 27/2/2024 14:13.
Abstract
Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within—and across—countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 22/7/2024 18:22